Spartalizumab - CAS 1935694-88-4

Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity. It blocks the interaction with PD-L1 and PD-L2, making it suitable for studying undifferentiated thyroid cancer (ATC) .

PD-1/PD-L1

Cell Cycle/Checkpoint, Immunology/Inflammation, Apoptosis

1935602

0.963

-20°C

Ice Packs

Inhibitory Antibodies